qepler

- 12+ Program Hours
- Networking
- Panel Discussions | Q & A
- Video Recording

SPONSORS

intertek
Total Quality. Assured.



2nd Annual

INHALED DRUG DELIVERY SUMMIT 2021

5-6 August 2021

hopin

● VIRTUAL CONFERENCE

12:00 - 19:00 CEST (Prague - UTC/GMT +2 hours)

qepler

SPEAKERS BOARD

Dr. Andrew Feilden, CSci CChem FRSC
European E&L strategic Director
Hall Analytical, UK

Dr. John N Pritchard
Independent Business Owner
Inspiring Strategies, UK

Dr. Herbert Watchel
Senior Principal Scientist
Boehringer Ingelheim
Pharma GmbH & Co. KG, DE

Dr. Felix Weiland
Head of Product & Process Technology
Boehringer Ingelheim microParts
GmbH, DE

Thomas Sécher
Senior Postdoctoral Fellow
INSERM, FR

Dr. Carsten Ehrhardt
Professor in Pharmaceutics and Biopharmaceutics
Trinity College
Dublin, IE

TBA

AlveoliX AG, CH

WHO YOU WILL MEET

qepler

intertek
Total Quality. Assured.

Tel: +41 61 686 4800
Fax: +44 61 686 4899
Email: business.support@intertek.com
Website: www.intertek.ch

Intertek is the industry leader with over 42,000 people in 1,000 locations in over 100 countries. Whether your business is local or global, we can ensure your products meet quality, health, environmental, safety, and social accountability standards for virtually any market around the world. We hold extensive global accreditations, recognitions, and agreements, and our knowledge of and expertise in overcoming regulatory, market, and supply chain hurdles is unrivaled.

Intertek (Schweiz) AG provides a comprehensive range of Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) compliant analytical services including chemical trace analysis, reverse engineering, complex analyses, substance identification, method development, and a wide range of other applications in conjunction with consulting expertise and engineering support.

Intertek - WEBINARS:

- Webinar Recording: Repurposing Products for Inhaled Delivery - Rapid Response Strategies
  https://www.intertek.com/knowledge-education/webinars/rapid-repurposing-for-inhaled-delivery/
- Webinar: Formulation and Manufacturing Approaches for Nasal Drug Products
  https://www.intertek.com/knowledge-education/webinars/webinar-formulation-nasal-drug-products/
- Article: In Vitro Bioequivalence for Pulmonary and Nasal Delivery
  https://www.intertek.com/knowledge-education/invitro-bioequivalence-generic-oindp-article/

SNAPSHOT OF ATTENDEES - VIRTUAL 2nd Annual Extractables & Leachables Conference 2020:

3P Biopharmaceuticals, ES - Abbott Healthcare Products B.V., NL - Abbvie Deutschland GmbH & Co. KG, DE - Accord-UK Ltd, UK - Advent Consulting Canada, CA - ALK, DK - Alkermes Pharma Ireland Limited, IE - Alphamed Formulations PVT LTD, IN - Apotex Research Pvt Ltd., IN - Aspen Holdings, ZA - Aspen Pharmacare, ZA - B.Braun medical SA, CH - Bavarian Nordic, DK - Becton Dickinson, CN - Becton Dickinson, FR - Biogen, USA - Boston Analytical, USA - Claudia Cusa, d.i., IT - CSL Behring AG, CH - Datwyler Pharma Packaging International NV, BE - DuPont, USA - DuPont-Asahi Flash Spun Products, JP - EirGen Pharma, IE - Eli Lilly and Company, USA - EMS SA, CH - Eurofins Analytical Science Laboratories, Inc., JP - Fujifilm Diosynth Biotechnologies, UK - GSK, US - GSK Vaccines, BE - Hall Analytical, UK - Hemofarm AD, RS - HTL-Strefa S.A., PL - Intertek (Schweiz) AG, CH - Janssen, USA - Kora Healthcare, IE - LEO Pharma, IE - Maven E&L Ltd, UK - Medline Industries, USA - Merck KGaA, DE - MilliporeSigma a business of Merck KGaA, USA - Novartis, CH - Novartis Pharma Stein AG, CH - NOVAVAX CZ a.s., CZ - Orexo AB, SE - Orion Corporation - FI, Philips, NL - Polifarma İlaç San. ve Tic. A.Ş., TR - PPD, IE - Rentschler Biopharma SE, DE - Safetree Consulting e.U., AT - Sandoz Manufacturing Inc., CA - Sanofi, FR - Sanofi, DE - Sanofi Pasteur, CA - Sartorius Stedim Biotech GmbH, DE - SCHOTT AG, DE - SCIEX, UK - Selvita S.A., PL - Septodont, FR - SGS, CN-TW - SGS Institut Fresenius GmbH, DE - Solvias AG, CH - Sthree, BE - Swedish Biomimetics 3000 Ltd, UK - Takeda Pharmaceuticals, USA - Vet-Agro Sp. z o.o., PL - West Pharmaceutical Services, USA - Wockhardt Ltd, IN - and others.

Agenda: https://qepler.com/agendas/agenda-2nd-extractables-and-leachables-20.pdf

POSITIONS

- C-Level, Presidents, Chairs, Members of the Board & VPs
- Vice presidents, Directors, & Heads
- Leaders & Managers
- Principals, Engineers, Analysts & Scientists
- Instructors & Trainers & Teachers
- Advisors, Coordinators, Auditors & Consultants
- Other Professionals, Experts & Specialists

DIVISIONS

- Aerosol Science
- Asthma
- Combination Products
- Connective Health
- COPD
- Cystic Fibrosis
- Device Development & Engineering
- Drug Development & Delivery
- Dry Powder Inhalers
- E-Health
- Formulation Development
- Formulation Development
- Generics
- Inhalation Delivery
- Inhalation Product Development
- Inhalation Products
- Inhaled Dosage Forms
- Medical Devices
- Metered Dose Inhalers
- Nasal Delivery
- New Materials
- Particle Characterisation
- Process Development
- Pulmonary Delivery
- Pulmonary Diseases
- R&D
- Regulatory Affairs
- Respiratory Delivery
- Respiratory Drug Delivery & Development
- Respiratory Supply Chain
- Respiratory Therapeutics
- Respiratory Pharmacology
- Scientific Research
- Marketing & Business Development
- Other

INDUSTRIES

- Pharmaceutical
- Biotechnology
- Chemical
- Medical Devices
- Plastics
- CMOs/CDMOs
- CROs
- NOPs
- Regulatory Agencies
- Training providers
- Other

INHALED
DRUG DELIVERY

qepler
INHALED
DRUG DELIVERY
VIRTUAL SUMMIT
2021

PROPOSED TOPICS

- Aerosol science and technology for pulmonary and nasal drug delivery.
- Modelling, simulation, response control, aerosol dynamics, particle engineering.
- RAerosol deposition: New in vitro and in vivo testing methods. Optimising lung deposition. In vitro – in vivo comparability.
- Inhalation toxicology studies.
- Cell culture models in IDD.
- Microfluidic tissue chips for respiratory health.
- Predictive models for respiratory therapies.
- New therapeutic opportunities. Development and formulation of emerging aerosol medicines: from smart nebulizers to vaccines.
- Inhaled triple therapy.
- Pulmonary immune-modulation.
- Pulmonary hypertension.
- Paediatric aerosol therapy.
- Inhaled therapies of repurposed drugs.
- Chronic lung disease.
- Respiratory delivery of biologics.
- Considerations for new pathologies.
- Regulatory evolution, compliance and considerations. Adoption strategies. Brining device to the market.
- Preparing for EU MDR implementation and its implications on inhaled combination products. EU MDR Impact on manufacturer.
- Advanced inhaled drug delivery technologies.
- Digital Health in IDD: advances in digital technologies, opportunities and associated challenges overcome. Digitalization perspectives for inhaled therapies. Smart devices to enhance patient adherence. Mobile applications in healthcare. AI assistance. Regulatory implications and adoption barriers. Customer side of digital health.
- Connected digital technologies and next generation combination products.
- Patient centricity: selecting right device, training and educating patient, transforming the patient experience and adherence.
- Developing effective training devices. Human centred approach.
- Life cycle management.
- Human factors studies implementation. Utilizing HF in device development. HF engineering for medical device development.
- Inhaled combination product design. New drug design technologies. Technical and usability considerations. Material selection.
- Analytical approaches and techniques. Drug/device compatibility, safety evaluation and testing.
- Manufacturing of delivery devices. Applying QBD principles in new inhaled drug development. Risk-based approaches to design and development of drug delivery systems.
- Powder Dosing and Innovative development of dry powder inhalers: from formulation, through bioequivalence testing, human factor issues, new delivery platforms to final regulatory approval.
- Developing the metered-dose inhalers: unlocking the market potential and opportunities, targeting therapy, boosting manufacturing process, preparing for the regulations approval.
- Emerging nebulised therapies and device development.
- Liquid inhalers: formulation, device design and development.
- Developing generic inhaled products. A generic manufacturer point of view.



INHALED DRUG DELIVERY

qepler

INHALED
DRUG DELIVERY
VIRTUAL SUMMIT
2021

August 5 | 1st DAY

Central European Time (CEST, Prague, UTC/GMT +2 hour)

12:00 - 12:20	**Registration**
12:20 - 12:30	**Opening Address from the Chairman**
12:30 - 13:00	Case Study #1
13:00 - 13:10	**Q & A**
13:10 - 13:40	Case Study #2
13:40 - 13:50	**Q & A**
13:50 - 14:00	**Break**
14:00 - 14:30	Case Study #3
14:30 - 14:40	**Q & A**
14:40 - 15:10	Case Study #4
15:10 - 15:20	**Q & A**



INHALED DRUG DELIVERY

qepler

INHALED
DRUG DELIVERY
VIRTUAL SUMMIT
2021

August 5 | 1st DAY

Central European Time (CEST, Prague, UTC/GMT +2 hour)

15:20 - 15:50	Reserved **SPONSOR** intertek Total Quality. Assured.
15:50 - 16:00	Q & A
16:00 - 16:10	Break
16:10 - 16:40	Case Study #5
16:40 - 16:50	Q & A
16:50 - 17:20	Case Study #6
17:20 - 17:30	Q & A
17:30 - 18:30	Panel discussion
18:30 - 18:40	Closing remarks and end of Day 1

INHALED DRUG DELIVERY

qepler

INHALED
DRUG DELIVERY
VIRTUAL SUMMIT
2021

August 6 | 2nd DAY

Central European Time (CEST, Prague, UTC/GMT +2 hour)

12:00 - 12:20	**Registration**
12:20 - 12:30	**Opening Address from the Chairman**
12:30 - 13:00	Case Study #1
13:00 - 13:10	**Q & A**
13:10 - 13:40	Sponsorship presentation **SPONSOR**
13:40 - 13:50	**Q & A**
13:50 - 14:00	**Break**
14:00 - 14:30	Case Study #2
14:30 - 14:40	**Q & A**
14:40 - 15:10	Case Study #3
15:10 - 15:20	**Q & A**



INHALED DRUG DELIVERY

qepler

INHALED
DRUG DELIVERY
VIRTUAL SUMMIT
2021

August 6 | 2nd DAY

Central European Time (CEST, Prague, UTC/GMT +2 hour)

15:20 - 15:50	Sponsorship presentation — **SPONSOR**
15:50 - 16:00	Q & A
16:00 - 16:10	Break
16:10 - 16:40	Case Study #4
16:40 - 16:50	Q & A
16:50 - 17:20	Case Study #5
17:20 - 17:30	Q & A
17:30 - 18:00	Case Study #6
18:00 - 18:10	Q & A
18:10 - 18:20	Closing remarks and end of summit

SPEAKER'S BIOGRAPHIES

Dr. Andrew Feilden
European E&L strategic Director
Hall Analytical, UK

Dr. Andrew Feilden is the European E&L strategic Director at Hall Analytical. Prior to that he was the Chemistry Operations Director, for 6 years, where he lead the chemistry group at the Shawbury site in the UK. The Shawbury site carries out extractable and leachable testing, GPC analysis and food contact testing. He has delivered numerous international podium presentations on Extractables and leachables.
Andrew has been with Smithers for over 7 years, prior to that he worked for AstraZeneca, specialising in Extractables and Leachables. He has a degree and D Phil from the university of York, is a Fellow of the Royal Society of Chemistry and is a Scientific advisor to IPAC-RS.

Dr. Felix Weiland
Head of Product & Process Technology
Boehringer Ingelheim microParts GmbH, DE

Felix is a pharmacist by training with a PhD in pharmacology. In 2006, he joined Boehringer Ingelheim as a trainee, focusing on launch and transfer activities of inhalative products. He then took over different roles at BI microParts in Dortmund at the development site of inhalation devices as development QA manager, senior project manager, and lab head of device development. In 2010, he joined the Ger-resheimer Group at Bünde as a QC head and later as quality director. Buende is a large-scale manufacturing site of sterile primary packaging components, i.e.RTF®- syringes and insulin cartridges. In 2015, he returned to Boehringer Ingelheim to implement systems for systematic life cycle management of the Respimat® Plat¬form Technology, including ownership of the design history files. Currently he is the director of product- & process-technology including responsibilities for project management, design verification laboratories, clinical trial supply, and design & process technology of devices.

Dr. Herbert Watchel
Senior Principal Scientist
Boehringer Ingelheim Pharma **GmbH & Co. KG, DE**

Dr. Herbert Wachtel is a Senior Principal Scientist at Boehringer Ingelheim, Germany. Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies. Within its business unit Prescription Medicines, Respiratory is one of the major areas. Herbert has joined the company in 1998 and since then he has been involved in basics of inhalation therapy, e.g. formulation development, novel methods for particle sizing, design of aerodynamic components in inhalers and aerosol therapy in children. In his spare time Herbert serves as a lecturer on the subject of Pharmaceutical Technology at the Johannes Gutenberg-University in Mainz.
Herbert has studied Physics at the University of Stuttgart where he investigated conducting molecular solid films and surfaces before switching to the field of aerosolized drug delivery. Apart from CAD tools, Herbert regularly applies Computational Fluid Dynamics (CFD) and he advances up-to-date 'in vivo-in vitro correlations' (IV-IVC) for the optimization of devices in the industrial setting.

Dr. Carsten Ehrhardt
Professor in Pharmaceutics and Biopharmaceutics
Trinity College Dublin, IE

Carsten Ehrhardt is Professor in Pharmaceutics at the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin. In addition, he is holding an Adjunct Professorship at the School of Pharmacy, University of Southern California. He was elected Fellow of Trinity College Dublin in 2013. Carsten obtained his Ph.D. in Biopharmaceutics from Saarland University in 2003. His research is focused on lung drug disposition, pulmonary epithelial transport and molecular origins of airways disease. He has edited 1 book and (co-)authored 91 peer-reviewed publications and more than 230 abstracts and conference proceedings. Carsten has given over 120 invited oral presentations. He is the proud recipient of honours and awards from DPhG, APS and Galenus Foundation. Carsten actively serves on the Editorial Boards of the American Journal of Physiology - Lung Cellular and Molecular Physiology, European Journal of Pharmaceutics and Biopharmaceutics, European Journal of Pharmaceuticals Sciences, Journal of Aerosol Medicine and Pulmonary Drug Delivery and Journal of Pharmaceutical Sciences.

Dr John N Pritchard
Independent Business Owner
Inspiring Strategies, UK

From January 2011 - September 2018, John was CTO for Philips Respironics Drug Delivery, with global accountability for the development of products for the treatment of respiratory diseases. He is now a private consultant specialising in strategic approaches to developing respiratory devices, drugs and digital health. At different stages in his career across 3 major pharmaceutical companies, he has been associated with the launch of 11 major products and at RDD in April 2018, John received the Charles Thiel award for outstanding research and discovery in respiratory drug delivery. John has published widely in the field, as well as having served as Board member on various scientific and industry bodies. He has sat on a number of Advisory Boards and is currently a member of the UN Committee that makes recommendations on the essential uses of propellants.

qepler

REGISTRATION FORM

This registration form is editable.
When you have completed the form - please save and email it to register@qepler.com

SUMMIT NAME: VIRTUAL - 2nd Annual Inhaled Drug Delivery Summit 2021

REGISTRATION DATE:

PACKAGE NAME	Standard price	
Individual ticket - 1st Day (5th August 2021) - (*includes 1st Day's post-event conference materials distribution)	€195	☐
Individual ticket - 2nd Day (6th August 2021) - (*includes 2nd Day's post-event conference materials distribution)	€195	☐
Individual ticket - 2 Days - (*includes complete post-event conference materials distribution)	€295	☐
Group ticket - 2 Days (*2-3 delegates) - (*includes complete post-event conference materials distribution)	€215	☐
Group ticket - 2 Days (*4+ delegates) - (*includes complete post-event conference materials distribution)	€145	☐
Documentation package - (*if you have no plans to join the live conference)	€495	☐
Promotional materials distribution	€445	☐
SPEAKER SPONSOR - €995 ☐	PARTNER SPONSOR - €1295 ☐	GOLD SPONSOR - €1695 ☐

CONFERENCE MATERIALS:
All participation tickets, already contains complete conference materials distribution package, including - slides, list of participants, stream and video recording. You don't need to order an additional «Documentation Packages».
Documentation package will be sent to the attendees within 72 hours after the event. The presentation content is subject to speaker's companies approval for distribution.

ATTENDEE DETAILS	1ST ATTENDEE	2ND ATTENDEE	3RD ATTENDEE	4TH ATTENDEE	5TH ATTENDEE	6TH ATTENDEE
Title:						
Name:						
Surname:						
Company:						
Country:						
Job Title:						
Direct phone:						
Email:						
Special Requirenments: (If you have any special dietary requirements or other needs that would enhance your enjoyment of this summit, please specify)						

INVOICE DETAILS:

Title: _____ Name: _____ Surname: _____

Job Title: _____

Direct Phone: _____ Mobile: _____ Email: _____

Company: _____ Country: _____ City: _____ EU VAT #: _____

Address: _____ Postcode: _____

Payment Method:

Bank Transfer ☐ Credit Card ☐ Pay Pall ☐

TERMS & CONDITIONS:

REGISTRATION & PAYMENT
Upon receiving the signed registration form, we will process your application. The registration confirmation and the invoice will be sent to you within one (1) working day with the relevant payment instructions and terms. The registration fee includes access to all sessions and conference materials. Payment is due 14 working days from the invoice date. Payment should be made by Credit Card, Pay Pall or by Bank Transfer. The delegate is responsible for any bank charges/fees associated with the payment.

CANCELLATION & SUBSTITUTION POLICY
You may substitute a delegate at any time and at no extra cost. Cancellations must be in a written notice. Cancellations made 30 days or more before the event start date will be refunded less than 50% of the registration fee. Cancellations made less than 30 days before the event start date will receive no refund. If you cannot attend an event due to illness or other unforeseen circumstances, you may transfer your delegate pass to another upcoming event within one year from original event start date.

EVENT CHANGES & CANCELLATIONS
While all effort will be made to adhere to the advertised package, Qepler s.r.o. reserves the right to change event dates, sites or location, omit event features, or merge the event with another event as it deems necessary without penalty. In such situations no refunds, part refunds or alternative offers will be made. In the event that Qepler s.r.o. permanently cancels the event for any reason, and provided that the event is not postponed to a later date nor is merged with another event, you will receive a credit note or refund for 100% of the conference fee paid. Please note, Qepler s.r.o. will not be held liable for any accommodation or associated travel costs should the event be canceled or rescheduled.

DATA PROTECTION
The personal information provided by you will be held in the Qepler database. It may be used to infrom you about other Qepler products and services. Unless you click here ☐, your details may be made available to third parties for marketing purposes.
For data update please write to databasemanager@qepler.com.

Signature:
«I agree to be bound by Terms and Conditions of registration»

PARTICIPATION PACKAGES

qepler

ONLINE PACKAGES:

If you are unable to attend, you may purchase these packages

PACKAGE NAME	PRICE
DOCUMENTATION (*if you have no plans to join the live conference) Post-event presentations with video records, list of participants and other materials. The presentation content is subject to speaker's companies approval for distribution.	€495
PROMOTIONAL MATERIALS DISTRIBUTION Distribution of your company's promotional materials to all attendees	€445

SPONSORSHIP PACKAGES:

BENEFITS	SPEAKER €995	PARTNER €1295	GOLD €1695
Number of passes included	1	2	3
Registration fee for additional company representatives	€195	€145	€95
Link to Landing Page/Video Presentation trough the live event translation.		•	•
Link to Virtual Exhibition Page trough the live event translation.			•
Opening keynote presentation			15 min
Speaking slot	20 min	30 min	30 min
Workshop slot			40 min
Recognition in chairman's opening address		•	•
Opening & closing speech			•
Chairman of Day 1			•
Chairman of Day 2		•	
Logo and URL on summit website, agenda and pre/post-summit communication activities	•	•	•
Recognition on Qepler social media channels (LinkedIn/Facebook/Twitter/Instagram)	•	•	•
Color advert placed on agenda		1/2 Page	1 Page
Online distribution of your company's promotional materials to all attendees		•	•

MARKETING CAMPAIGN

▸ Website ▸ Email Marketing ▸ Digital Advertising ▸ Social Marketing ▸ Press ▸ Direct Sales

PARTICIPATION FEE

Fees are inclusive of the complete summit materials, online post-event documentation/presentation package, list of participants, video records, and certificate of participation.

TRANSLATION

The event translation link will be announced online and sent to the delegates within a reasonable period before the summit start date.

POST-EVENT DOCUMENTATION

Presentations and other materials will be sent to the attendees within 72 hours after the event. The presentation content is subject to speaker's companies approval for distribution.

DISCOUNTS

Early booking discounts are not valid in conjunction with any other offers.

www.qepler.com

+420 608 030 490

register@qepler.com

WAYS TO REGISTER

EVENTS CALENDAR 2021

Please **choose** the **Summit / Summits** and **send** us suggested **Session Title** via email or webpage.
We will appreciate if you **share** our **calendar with** your **colleagues**!

qepler

CLICK HERE TO REQUEST INFORMATION

PHARMA - MEDICAL DEVICES - CHEMISTRY

DRUG DELIVERY - FORMULATION - R&D - DEVICES - COMBINATION PRODUCTS - PFS - LYOPHILIZATION - E & L - IMPURITIES - HPAPI - INHALATION - ASEPTIC PROCESSING - MDR - CMC - QRM - PFS - DDC - EM

Highly Potent APIs Webinar Day ..... June 25, 2021
- VIRTUAL

Enhance expertise sharing in developing pre-filled syringes and provide attendees with ample networking opportunities.
https://qepler.com/pdf/vhpapi21.pdf
REGISTRATION IS OPEN
AGENDA WEB

Medical Device Regulations Summit ..... July 8-9, 2021
- VIRTUAL CONFERENCE

Exploring EU MDR and IVDR updates and preparing company for new requirements implementation.
https://qepler.com/pdf/vmdr21.pdf
REGISTRATION IS OPEN
AGENDA WEB

2nd Genotoxic Impurities in Pharmaceuticals Summit ..... July 15-16, 2021
- VIRTUAL CONFERENCE

GTI strategies & new methodologies: analysis, in silico & regulations. Challenges & opportunities.
https://qepler.com/pdf/v2gti21.pdf
REGISTRATION IS OPEN
AGENDA WEB

3rd Annual Pharmaceutical Lyophilization Summit ..... July 29-30, 2021
- VIRTUAL CONFERENCE

Discuss best practices in tech & regulatory updates, process, formulation, testing, monitoring, new products development.
https://qepler.com/pdf/v3lyo21.pdf
REGISTRATION IS OPEN
AGENDA WEB

2nd Annual Inhaled Drug Delivery Summit ..... August 5-6, 2021
- VIRTUAL CONFERENCE

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
https://qepler.com/pdf/v2idd21.pdf
REGISTRATION IS OPEN
AGENDA WEB

3rd Annual Highly Potent APIs Summit ..... October 7-8, 2021
- VIRTUAL CONFERENCE

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
https://qepler.com/pdf/v3hpapi21.pdf
REGISTRATION IS OPEN
AGENDA WEB

3rd Annual Extractables & Leachables Summit ..... October 20-21, 2021
- VIRTUAL CONFERENCE

Get the latest updates in regulation, analytical testing, risk & safety assessment, biocompatibility.
https://qepler.com/pdf/v3el21.pdf
REGISTRATION IS OPEN
AGENDA WEB

3rd Annual Drug/Device Combination Products Summit ..... December 2-3, 2021
- VIRTUAL CONFERENCE

Get up to date with the regulatory and quality compliance strategies for combination product development.
https://qepler.com/pdf/v3ddcp21.pdf
REGISTRATION IS OPEN
AGENDA WEB

CONTACTS

Please send your session title and summit name to:

Denis Polikarpov
Executive Director
Tel: +420 608 030 490
Email: denis.polikarpov@qepler.com

Evgenia Makar
CEO
Tel: +420 770 699 211
Email: evgenia.makar@qepler.com